Health
Brazzein Sweetener Lowers Post‑Ice Cream Blood Sugar in Metabolic Disorder Study

A randomized trial published in Clinical Nutrition ESPEN examined the effect of the sweet protein brazzein on post‑meal blood glucose in 101 adults with metabolic dysfunction‑associated steatotic liver disease (MASLD). Participants consumed a 100‑gram vanilla ice cream on three separate days: one sweetened with sugar, one with brazzein, and one with brazzein plus the fiber inulin. Blood‑sugar spikes were lower after the brazzein‑sweetened servings, especially in those with type 2 diabetes, compared with the sugar‑sweetened version. The researchers noted that longer‑term studies are needed to determine whether repeated substitution of sucrose desserts with brazzein‑sweetened alternatives leads to sustained metabolic, hepatic, microbiome, or behavioral benefits. The World Health Organization, in 2023, cautioned against non‑sugar sweeteners for weight control, warning of potential long‑term risks such as type 2 diabetes and cardiovascular disease.
Frequently asked questions
What was the main finding of the brazzein study?
The study found that brazzein‑sweetened vanilla ice cream lowered post‑meal blood glucose spikes compared to sugar‑sweetened ice cream, especially in participants with type 2 diabetes.
How many participants were involved in the trial?
The randomized trial included 101 adults with metabolic dysfunction‑associated steatotic liver disease (MASLD).
What did the researchers say about the need for future studies?
The researchers noted that longer‑term studies are needed to determine whether repeated substitution of sucrose desserts with brazzein‑sweetened alternatives leads to sustained metabolic, hepatic, microbiome, or behavioral benefits.